Cart
sales@molnova.com
Lansoprazole sulfone
CAS No. 131926-99-3
Lansoprazole sulfone( —— )
Catalog No. M22591 CAS No. 131926-99-3
Lansoprazole sulfone is a metabolite of the gastric pump inhibitor Lansoprazole.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 110 | In Stock |
|
| 10MG | 205 | In Stock |
|
| 25MG | 439 | In Stock |
|
| 50MG | 644 | In Stock |
|
| 100MG | 888 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameLansoprazole sulfone
-
NoteResearch use only, not for human use.
-
Brief DescriptionLansoprazole sulfone is a metabolite of the gastric pump inhibitor Lansoprazole.
-
DescriptionLansoprazole sulfone is a metabolite of the gastric pump inhibitor Lansoprazole.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number131926-99-3
-
Formula Weight385.36
-
Molecular FormulaC16H14F3N3O3S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 250 mg/mL (648.74 mM)
-
SMILESCc1c(OCC(F)(F)F)ccnc1CS(=O)(=O)c1nc2ccccc2[nH]1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Zhang D , Yang M , Liu M , et al. Pharmacokinetics of lansoprazole and its main metabolites after single intravenous doses in healthy Chinese subjects[J]. Xenobiotica, 2012.
molnova catalog
related products
-
O-Succinylhomoserine
O-Succinylhomoserine is an intermediate in the synthesis of cystathionine by E coli..
-
Vilobelimab
Vilobelimab (CaCP-29, IFX-1), a monoclonal antibody targeting C5a, inhibits this pro-inflammatory complement component, which is pivotal in causing organ dysfunction.
-
MSBN
MSBN is a highly selective fluorescent probe for mercaptans that can selectively image mercaptans in living cells and specifically label protein mercaptans by switching on the signal to identify various reversible protein mercaptans modifications.
